BiotechTube

patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

TTR-mediated Amyloidosis

Conditions

TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related

Trial Timeline

Nov 1, 2013 → Aug 1, 2017

NCT ID
NCT01960348

About patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)

patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl) is a phase 3 stage product being developed by Alnylam Pharmaceuticals for TTR-mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01960348. Target conditions include TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial.

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02053454Phase 1Completed
NCT01960348Phase 3Completed

Competing Products

7 competing products in TTR-mediated Amyloidosis

See all competitors
ProductCompanyStageHype Score
ALN-TTR02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
ALN-TTRSC (revusiran) for subcutaneous administrationAlnylam PharmaceuticalsPhase 2
32
PatisiranAlnylam PharmaceuticalsPhase 2
32
ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
Revusiran (ALN-TTRSC)Alnylam PharmaceuticalsPhase 2
32
ALN-TTR02 (patisiran) administered by intravenous (IV) infusionAlnylam PharmaceuticalsPhase 2
32
patisiran (ALN-TTR02)Alnylam PharmaceuticalsPre-clinical
23